Breakthrough FDA Approval: New Drug Shows 90% Response Rate in Rare Lung Cancer, Including Brain Metastases

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

Open the article to view the coverage from The AI Journal

Breakthrough FDA Approval: New Drug Shows 90% Response Rate in Rare Lung Cancer, Including Brain Metastases

New targeted therapy demonstrates powerful 90% response rate in ROS1+ lung cancer patients. First brain-penetrant treatment option for this rare cancer. See clinical data.